Proactive Investors
29 Jul 2026, 07:38 UTC · 2h ago
Allergy Therapeutics reports accelerated revenue growth in its second half
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
29 Jul 2026, 07:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Allergy Therapeutics expects double-digit revenue growth for the year ending June 2027. — A shift to double-digit growth driven by peak treatment seasons and regulatory transitions provides a strong positive catalyst for the stock.
+0.60Allergy Therapeutics' second-half revenue is expected to reach £23.6 million, representing a growth acceleration to over 12% compared to 7% in the first half. — Accelerating revenue growth suggests improving momentum and product adoption.
+0.40Allergy Therapeutics increased its year-end cash position to £24.2 million after securing a new £40 million secured facility from Hayfin. — Improved liquidity and access to capital reduce short-term financial risk.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Cordiant Digital Infrastructure has reached approximately 80% contracted capacity at its Hudson Interxchange data centre in New York. — High capacity utilization indicates strong demand and moves the asset closer to full revenue potential.
+0.30Which stocks this story touches
Company reported accelerated revenue growth and provided positive guidance for the current year.
Company secured two new customer agreements, increasing contracted capacity at its New York data centre.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
2h ago
